3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
26
Leukemia, Myeloid, Acute
24
Recurrence
12
Sarcoma
7
Lymphoma, Large B-Cell, Diffuse
6
Neoplasm Metastasis
5
Neurofibrosarcoma
4
Neoplasms, Plasma Cell
4
Lymphoma
4
Triple Negative Breast Neoplasms
3
Ovarian Neoplasms
3
Myelodysplastic Syndromes
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Extranodal NK-T-Cell
3
Lymphoma, B-Cell
3
Thymoma
2
Rhabdoid Tumor
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Melanoma
2
Lymphoma, Mantle-Cell
2
Liposarcoma
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Biphenotypic, Acute
2
Leukemia
2
Congenital Abnormalities
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Breast Neoplasms
2
Wilms Tumor
1
Interventions
Dexamethasone
16
Calcium Dobesilate
9
Melphalan
6
Lenalidomide
6
Cyclophosphamide
5
Bortezomib
5
pomalidomide
3
venetoclax
2
daratumumab
2
Thalidomide
2
Doxycycline
2
Biopsy
2
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
2
selinexor
1
pegfilgrastim
1
ixazomib
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
carfilzomib
1
belantamab mafodotin
1
auricularum
1
Vinorelbine
1
Technetium Tc 99m Pyrophosphate
1
Technetium
1
Tacrolimus
1
Surveys and Questionnaires
1
Interleukin-2
1
In Situ Hybridization, Fluorescence
1
In Situ Hybridization
1
Hyaluronoglucosaminidase
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Amyloidosis
×
selinexor
×
Clear all
NCT04984330
2022-11-17
STARR
Weill Medical College of Cornell University
Phase EARLY_PHASE1
Withdrawn